In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Global Retirement Partners LLC trimmed its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) by 19.8% during the ...

Alcoholic and non-alcoholic fatty liver disease (NAFLD) are well-known risk factors for colorectal cancer (CRC). NAFLD has ...

We came across a bullish thesis on Viking Therapeutics, Inc. (VKTX) on Substack by Kontra Investments. In this article, we ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are covering the firm, Ratings reports. One equities ...

Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

Citi analyst David Lebowitz maintained a Hold rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $38.00.